Related Experiment Videos
[Is hypofibrinolysis a risk factor of thrombosis?]
La Revue Du Praticien
|November 11, 1989
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Prothrombin G20210A carriers the genetic mutation and a history of venous thrombosis contributes to thrombin generation independently of factor II plasma levels.
Journal of thrombosis and haemostasis : JTH·2010
Adipocytokines and the risk of coronary heart disease in healthy middle aged men: the PRIME Study.
International journal of obesity (2005)·2009
Activated thrombin activatable fibrinolysis inhibitor levels are associated with the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study.
Journal of thrombosis and haemostasis : JTH·2008
Polymorphisms of the tumor necrosis factor-alpha (TNF) and the TNF-alpha converting enzyme (TACE/ADAM17) genes in relation to cardiovascular mortality: the AtheroGene study.
Journal of molecular medicine (Berlin, Germany)·2008
Chronic plasminogen activator inhibitor-1 (PAI-1) overexpression dampens CD25+ lymphocyte recruitment after lipopolysaccharide endotoxemia in mouse lung.
Journal of thrombosis and haemostasis : JTH·2007
[In utero treatment of twin-to-twin transfusion syndrome].
La Revue du praticien·2026
[In utero treatment of spina bifida].
La Revue du praticien·2026
[Syphilis and pregnancy].
La Revue du praticien·2026
[Second-line treatments for Parkinson's disease].
La Revue du praticien·2026
[Ageism in healthcare: sad prejudices!]
La Revue du praticien·2026
[Vaccination for pregnant women].
La Revue du praticien·2026
Prognostic Role of Blood Inflammatory Composite Biomarkers in Dvt After Lower Extremity Fractures.
The Iowa orthopaedic journal·2026
Pattern of blood utilization and blood wastage at blood bank of a tertiary care hospital in Lahore.
Pakistan journal of medical sciences·2026
Coagulation potential of concomitant factor VIII administration in people with hemophilia A receiving emicizumab prophylaxis (CAGUYAMA study): a multicenter, open-label, nonrandomized clinical trial.
Research and practice in thrombosis and haemostasis·2026
Management and outcomes in patients with cryptogenic stroke and weakly positive antiphospholipid antibodies.
Research and practice in thrombosis and haemostasis·2026